Review
Nature Reviews Drug Discovery 3, 673-683 (August 2004) | doi:10.1038/nrd1468
Drug repositioning: identifying and developing new uses for existing drugs
Ted T. Ashburn1 & Karl B. Thor1 About the authors
Abstract
Biopharmaceutical companies attempting to increase productivity through novel discovery technologies have fallen short of achieving the desired results. Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of production to biotechnology companies. More and more companies are scanning the existing pharmacopoeia for repositioning candidates, and the number of repositioning success stories is increasing.
- View At a Glance
Author affiliations
- Dynogen Pharmaceuticals, Inc., 31 St James Avenue, Suite 905, Boston, Massachusetts 02116, USA.
Correspondence to: Ted T. Ashburn1 Email: tashburn@dynogen.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mycobacterial virulence and specialized secretion: same story, different endingNature Medicine News and Views (01 Mar 2007)
